MARKET

NRIX

NRIX

Nurix Therapeutics, Inc.
NASDAQ
15.91
-0.12
-0.75%
After Hours: 15.91 0 0.00% 16:10 04/13 EDT
OPEN
16.16
PREV CLOSE
16.03
HIGH
16.80
LOW
15.90
VOLUME
980.34K
TURNOVER
--
52 WEEK HIGH
22.50
52 WEEK LOW
8.18
MARKET CAP
1.65B
P/E (TTM)
-5.0348
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NRIX last week (0406-0410)?
Weekly Report · 19h ago
Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Neogen (NEOG) and Nyxoah (NYXH)
TipRanks · 3d ago
HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Nurix Therapeutics (NRIX)
TipRanks · 3d ago
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide
Seeking Alpha · 4d ago
Nurix Therapeutics Price Target Cut to $28.00/Share From $29.00 by Wells Fargo
Dow Jones · 4d ago
Nurix Therapeutics Is Maintained at Overweight by Wells Fargo
Dow Jones · 4d ago
More
About NRIX
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Webull offers Nurix Therapeutics Inc stock information, including NASDAQ: NRIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NRIX stock methods without spending real money on the virtual paper trading platform.